Dalhousie University

Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease (2026) Cavender MA, Marx N, Mulvagh SL, Deanfield JE, Buse JB, Inzucchi SE, Pop-Busui R, et al. Journal article Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (2026) Mann JF, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, Mulvagh SL, et al. Journal article World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa (2026) Himmerich H, Keeler JL, King JA, Ehrlich S, Kaufmann LK, Bulik CM, Cohen-Woods S, et al. Journal article, Review article Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial (2026) Langley RG, Arkin L, Fiorillo L, Eichenfield LF, Lebwohl M, Strober B, Sticherling M, et al. Journal article Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes (2026) Pop-Busui R, Rasmussen S, Deanfield JE, Buse JB, Marx N, Mulvagh SL, Inzucchi SE, et al. Journal article Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials (2026) Müller-Wieland D, McGuire DK, Lincoff AM, Buse JB, Mann JF, Inzucchi SE, Pop-Busui R, et al. Journal article Correction to: Fine-mapping genomic loci refines bipolar disorder risk genes (Nature Neuroscience, (2025), 28, 7, (1393-1403), 10.1038/s41593-025-01998-z) (2025) Koromina M, Ravi A, Panagiotaropoulou G, Schilder BM, Humphrey J, Braun A, Bigdeli T, et al. Journal article, Erratum Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder (2025) Sharew NT, Clark SR, Papiol S, Heilbronner U, Degenhardt F, Fullerton JM, Hou L, et al. Journal article Fine-mapping genomic loci refines bipolar disorder risk genes (2025) Koromina M, Ravi A, Panagiotaropoulou G, Schilder BM, Humphrey J, Braun A, Bidgeli T, et al. Journal article Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (2025) Marx N, Deanfield JE, Mann JF, Arechavaleta R, Bain SC, Bajaj HS, Bayer Tanggaard K, et al. Journal article